Tri-specific tumor-associated antigens (Tri-specific TAA)

Tri-specific tumor-associated antigens refer to a strategic combination of cell-surface proteins targeted by trispecific antibodies or engagers to enhance therapeutic precision and efficacy in oncology. Unlike traditional monoclonal or bispecific therapies, trispecific platforms engage three distinct epitopes or molecules, typically involving one or two tumor-associated antigens (such as HER2, BCMA, or GPRC5D) and immune effector components like CD3 for T-cell recruitment and CD28 for costimulation. This multi-valent approach is designed to overcome tumor heterogeneity, prevent immune escape through antigen loss, and increase the potency of the immune response within the tumor microenvironment. By 'anchoring' the therapeutic molecule to multiple points on the tumor cell surface, these agents can achieve higher selectivity and more robust immune synapse formation. Clinical development of drugs targeting these antigen combinations is currently focused on treating refractory hematological cancers and various solid tumors where single-antigen targeting has proven insufficient.

Other names

Tri-specific tumor-anchoring cell-surface antigensMulti-antigen tumor targetsTrispecific antibody targetsCombinatorial tumor-associated antigens

Trispecific molecules simultaneously bind to one or more tumor-associated antigens (TAAs) and effector cell receptors (such as CD3 on T cells or CD16 on NK cells) to facilitate immune synapse formation and targeted cytotoxicity. Some designs include a third arm for costimulation (e.g., CD28) or half-life extension (e.g., Albumin).